Het TweeSteden Ziekenhuis was een op 1 januari 1997 ontstaan ziekenhuis uit de fusie tussen van het St. Nicolaas ziekenhuis in Waalwijk en het Maria ziekenhuis in Tilburg. Deze vestigingen gaven het ziekenhuis zijn naam en bestaan nog steeds, maar er is ook nog een Oisterwijkse polikliniek.

During the past decade, Elisabeth Tweesteden Ziekenhuis conducted 126 clinical trials. In the 10-year time frame, 126 clinical trials started and 36 clinical trials were completed, i.e. on average, 28.6% percent of trials that started reached the finish line to date. In the past 5 years, 56 clinical trials started and 23 clinical trials were completed. i.e. 41.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Elisabeth Tweesteden Ziekenhuis" #1 sponsor was "Radboud University Medical Center" with 19 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 10 trials sponsored, "Celgene" with 8 trials sponsored, "Eli Lilly and Company" with 7 trials sponsored and "Elisabeth-TweeSteden Ziekenhuis" with 7 trials sponsored. Other sponsors include 147 different institutions and companies that sponsored additional 85 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Elisabeth Tweesteden Ziekenhuis" #1 collaborator was "ZonMw: The Netherlands Organisation for Health Research and Development" with 14 trials as a collaborator, "Erasmus Medical Center" with 10 trials as a collaborator, "Elisabeth-TweeSteden Ziekenhuis" with 8 trials as a collaborator, "Dutch Cancer Society" with 7 trials as a collaborator and "Borstkanker Onderzoek Groep" with 6 trials as a collaborator. Other collaborators include 223 different institutions and companies that were collaborators in the rest 177 trials.

According to Clinical.Site data, the most researched conditions in "Elisabeth Tweesteden Ziekenhuis" are "Ulcerative Colitis" (15 trials), "Crohn's Disease" (10 trials), "Crohn Disease" (9 trials), "Breast Cancer" (6 trials) and "Prostate Cancer" (6 trials). Many other conditions were trialed in "Elisabeth Tweesteden Ziekenhuis" in a lesser frequency.

Most popular intervention types in "Elisabeth Tweesteden Ziekenhuis" are "Drug" (117 trials), "Other" (31 trials), "Procedure" (26 trials), "Device" (25 trials) and "Biological" (11 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (39 trials), "Mirikizumab" (5 trials), "Carboplatin" (4 trials), "Cisplatin" (4 trials) and "Ontamalimab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Elisabeth Tweesteden Ziekenhuis" are 174 trials for "All" genders, 18 trials for "Female" genders and 11 trials for "Male" genders.

Currently, there are 92 active trials in "Elisabeth Tweesteden Ziekenhuis". 3 are not yet recruiting, 46 are recruiting, 39 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 78 completed trials in Elisabeth Tweesteden Ziekenhuis, undefined suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in Elisabeth Tweesteden Ziekenhuis, 2 "Phase 1" clinical trials were conducted, 28 "Phase 2" clinical trials and 89 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 11 trials, and there were also 42 trials that are defined as “Not Applicable".